| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).
|
J Clin Oncol
|
2009
|
5.75
|
|
2
|
Skeletal metastases in non-small cell lung cancer: a retrospective study.
|
Lung Cancer
|
2007
|
2.88
|
|
3
|
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.
|
J Thorac Oncol
|
2013
|
2.33
|
|
4
|
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
|
J Clin Oncol
|
2010
|
1.51
|
|
5
|
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
|
Biochem Biophys Res Commun
|
2011
|
1.13
|
|
6
|
Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
|
Lung Cancer
|
2004
|
1.06
|
|
7
|
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
|
J Thorac Oncol
|
2009
|
1.02
|
|
8
|
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
|
Cancer
|
2012
|
0.99
|
|
9
|
Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.
|
Int J Cancer
|
2006
|
0.99
|
|
10
|
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
|
J Thorac Oncol
|
2015
|
0.92
|
|
11
|
Clinical response to crizotinib retreatment after acquisition of drug resistance.
|
J Clin Oncol
|
2013
|
0.84
|
|
12
|
Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
|
Jpn J Clin Oncol
|
2008
|
0.81
|
|
13
|
A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer.
|
PLoS One
|
2013
|
0.81
|
|
14
|
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
|
Cancer Chemother Pharmacol
|
2006
|
0.81
|
|
15
|
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
|
Cancer Chemother Pharmacol
|
2009
|
0.80
|
|
16
|
Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
|
Cancer
|
2013
|
0.79
|
|
17
|
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.
|
Cancer Sci
|
2012
|
0.79
|
|
18
|
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.
|
Invest New Drugs
|
2013
|
0.79
|
|
19
|
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer.
|
Clin Med Insights Oncol
|
2011
|
0.78
|
|
20
|
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
|
Am J Clin Oncol
|
2012
|
0.78
|
|
21
|
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
|
Eur J Cancer
|
2009
|
0.78
|
|
22
|
Role of consolidation chemotherapy after concurrent chemo-radiotherapy in locally advanced non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.77
|
|
23
|
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
|
Invest New Drugs
|
2012
|
0.77
|
|
24
|
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.77
|
|
25
|
Capecitabine plus Cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases.
|
Gastrointest Cancer Res
|
2012
|
0.75
|
|
26
|
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
|
Invest New Drugs
|
2012
|
0.75
|
|
27
|
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
|
Anticancer Res
|
2007
|
0.75
|
|
28
|
[Evidence-based practice guideline for unresectable advanced lung cancer in 2003].
|
Nihon Geka Gakkai Zasshi
|
2004
|
0.75
|
|
29
|
A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.
|
Anticancer Res
|
2006
|
0.75
|
|
30
|
Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.
|
J Thorac Oncol
|
2006
|
0.75
|
|
31
|
Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug.
|
Med Oncol
|
2007
|
0.75
|
|
32
|
Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes.
|
Anticancer Res
|
2004
|
0.75
|